Related references
Note: Only part of the references are listed.A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers
Jill M. Kolesar et al.
CANCER PREVENTION RESEARCH (2019)
Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation
Oukseub Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
A Randomized Phase II Presurgical Trial of Transdermal 4-Hydroxytamoxifen Gel versus Oral Tamoxifen in Women with Ductal Carcinoma In Situ of the Breast
Oukseub Lee et al.
CLINICAL CANCER RESEARCH (2014)
Abstract CN04-04: Phase II trial of bexarotene in women at high risk of breast cancer: Comparison of protein and RNA biomarkers
P. Brown et al.
Cancer Prevention Research (2012)
From carrot to clinic: an overview of the retinoic acid signaling pathway
Maria Theodosiou et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib
Daniel Medina et al.
CANCER PREVENTION RESEARCH (2009)
Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata
Rakhshandra Talpur et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
Y. Li et al.
BRITISH JOURNAL OF CANCER (2008)
The Novel Retinoid, 9cUAB30, Inhibits Telomerase and Induces Apoptosis in HL60 Cells
William K. Love et al.
TRANSLATIONAL ONCOLOGY (2008)
Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers
Clinton J. Grubbs et al.
CARCINOGENESIS (2006)
Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: A prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen
P Rouanet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
9cUAB30, an RXR specific retinoid, and/or tarnoxifen in the prevention of methylnitrosourea-induced mammary cancers
CJ Grubbs et al.
CANCER LETTERS (2003)
Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma
D Breneman et al.
ARCHIVES OF DERMATOLOGY (2002)
Share Paper
